Insufficient scRNA-seq data for expression of CAD at single-cell level.
Insufficient scRNA-seq data for expression of CAD at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2879.78 | 1445 / 1445 | 100% | 56.61 | 183 / 183 |
skin | 100% | 4501.75 | 1809 / 1809 | 100% | 55.31 | 471 / 472 |
ovary | 100% | 4754.34 | 180 / 180 | 100% | 46.37 | 429 / 430 |
intestine | 100% | 3089.86 | 966 / 966 | 99% | 41.06 | 523 / 527 |
uterus | 100% | 5096.85 | 170 / 170 | 99% | 39.95 | 455 / 459 |
breast | 100% | 3182.51 | 459 / 459 | 99% | 33.75 | 1107 / 1118 |
stomach | 99% | 2079.22 | 357 / 359 | 99% | 41.83 | 284 / 286 |
bladder | 100% | 3241.57 | 21 / 21 | 98% | 33.85 | 494 / 504 |
lung | 99% | 2716.08 | 573 / 578 | 98% | 36.93 | 1134 / 1155 |
thymus | 100% | 3952.63 | 653 / 653 | 96% | 21.21 | 583 / 605 |
pancreas | 100% | 2303.67 | 327 / 328 | 97% | 20.77 | 172 / 178 |
brain | 97% | 1876.52 | 2568 / 2642 | 99% | 26.55 | 697 / 705 |
prostate | 100% | 3263.37 | 245 / 245 | 95% | 18.57 | 479 / 502 |
kidney | 100% | 2348.43 | 89 / 89 | 86% | 15.57 | 779 / 901 |
liver | 100% | 2294.31 | 226 / 226 | 72% | 12.69 | 291 / 406 |
adrenal gland | 99% | 2398.63 | 255 / 258 | 62% | 8.01 | 143 / 230 |
adipose | 100% | 2797.30 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 46.14 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 45.17 | 29 / 29 |
spleen | 100% | 3893.39 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 38.52 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.83 | 1 / 1 |
blood vessel | 100% | 2350.30 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 93% | 1206.88 | 802 / 861 | 0% | 0 | 0 / 0 |
muscle | 93% | 1024.22 | 743 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 77% | 2634.53 | 713 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0033574 | Biological process | response to testosterone |
GO_0014075 | Biological process | response to amine |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0007507 | Biological process | heart development |
GO_0071364 | Biological process | cellular response to epidermal growth factor stimulus |
GO_0018107 | Biological process | peptidyl-threonine phosphorylation |
GO_0032868 | Biological process | response to insulin |
GO_0006541 | Biological process | glutamine metabolic process |
GO_0001889 | Biological process | liver development |
GO_0031100 | Biological process | animal organ regeneration |
GO_0006228 | Biological process | UTP biosynthetic process |
GO_0007565 | Biological process | female pregnancy |
GO_0042594 | Biological process | response to starvation |
GO_0006207 | Biological process | 'de novo' pyrimidine nucleobase biosynthetic process |
GO_0044205 | Biological process | 'de novo' UMP biosynthetic process |
GO_0006225 | Biological process | UDP biosynthetic process |
GO_0007595 | Biological process | lactation |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0031000 | Biological process | response to caffeine |
GO_0051414 | Biological process | response to cortisol |
GO_0019240 | Biological process | citrulline biosynthetic process |
GO_0016020 | Cellular component | membrane |
GO_0043195 | Cellular component | terminal bouton |
GO_0032991 | Cellular component | protein-containing complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0043025 | Cellular component | neuronal cell body |
GO_0016363 | Cellular component | nuclear matrix |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0042995 | Cellular component | cell projection |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0004088 | Molecular function | carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity |
GO_0004087 | Molecular function | carbamoyl-phosphate synthase (ammonia) activity |
GO_0070335 | Molecular function | aspartate binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0004359 | Molecular function | glutaminase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004151 | Molecular function | dihydroorotase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004070 | Molecular function | aspartate carbamoyltransferase activity |
Gene name | CAD |
Protein name | Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase CAD protein Multifunctional protein CAD (Carbamoyl phosphate synthetase 2-aspartate transcarbamylase-dihydroorotase) [Includes: Glutamine-dependent carbamoyl phosphate synthase (EC 6.3.5.5); Glutamine amidotransferase (GATase) (GLNase) (EC 3.5.1.2); Ammonium-dependent carbamoyl phosphate synthase (CPS) (CPSase) (EC 6.3.4.16); Aspartate carbamoyltransferase (EC 2.1.3.2); Dihydroorotase (EC 3.5.2.3)] Uncharacterized protein CAD |
Synonyms | |
Description | FUNCTION: Multifunctional protein that encodes the first 3 enzymatic activities of the de novo pyrimidine pathway: carbamoylphosphate synthetase (CPSase; EC 6.3.5.5), aspartate transcarbamylase (ATCase; EC 2.1.3.2) and dihydroorotase (DHOase; EC 3.5.2.3). The CPSase-function is accomplished in 2 steps, by a glutamine-dependent amidotransferase activity (GATase) that binds and cleaves glutamine to produce ammonia, followed by an ammonium-dependent carbamoyl phosphate synthetase, which reacts with the ammonia, hydrogencarbonate and ATP to form carbamoyl phosphate. The endogenously produced carbamoyl phosphate is sequestered and channeled to the ATCase active site. ATCase then catalyzes the formation of carbamoyl-L-aspartate from L-aspartate and carbamoyl phosphate. In the last step, DHOase catalyzes the cyclization of carbamoyl aspartate to dihydroorotate. . |
Accessions | ENST00000403525.5 G1UI39 H7BZB3 ENST00000456311.1 ENST00000458503.1 P27708 ENST00000428460.1 Q53SY7 H7C2E4 ENST00000264705.9 H7C3Z5 F8VPD4 Q53SZ4 |